Source:http://linkedlifedata.com/resource/pubmed/id/15247986
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2004-7-12
|
| pubmed:abstractText |
Human immunodeficiency virus infection is an illness with protean manifestations including hematological abnormalities. Thromboembolic complications in HIV-infected patients have been described. Recent literature describes an incidence ranging from 0.26% to 7.6%; higher incidence is seen in patients with active opportunistic infections or malignancy, and in patients with the acquired immunodeficiency syndrome. A variety of potential mechanisms have been proposed to account for the observed hypercoagulability in HIV-infected patients. These include the presence of antiphospholipid-anticardiolipin antibodies, decreased activities of natural anticoagulants (especially protein S), and increased platelet activation. Recent epidemiological studies emphasize the increased incidence of thromboembolic events including myocardial infarction in the HIV-infected population after the introduction of highly active antiretroviral therapy. The use of protease inhibitors in particular is implicated. A hypercoagulable state and especially thromboses are emerging as clinical issues in HIV-infected patients. Further studies are in order to more clearly delineate the pathophysiologic mechanism(s) of thromboses in HIV-infected patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Antiphospholipid,
http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants,
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Indinavir
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1076-0296
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
277-80
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading |
pubmed-meshheading:15247986-Adult,
pubmed-meshheading:15247986-Antibodies, Antiphospholipid,
pubmed-meshheading:15247986-Anticoagulants,
pubmed-meshheading:15247986-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15247986-Aspirin,
pubmed-meshheading:15247986-Cohort Studies,
pubmed-meshheading:15247986-HIV Infections,
pubmed-meshheading:15247986-HIV Protease Inhibitors,
pubmed-meshheading:15247986-Humans,
pubmed-meshheading:15247986-Incidence,
pubmed-meshheading:15247986-Indinavir,
pubmed-meshheading:15247986-Middle Aged,
pubmed-meshheading:15247986-Myocardial Infarction,
pubmed-meshheading:15247986-Platelet Activation,
pubmed-meshheading:15247986-Protein S Deficiency,
pubmed-meshheading:15247986-Retrospective Studies,
pubmed-meshheading:15247986-Risk Factors,
pubmed-meshheading:15247986-Thromboembolism,
pubmed-meshheading:15247986-Thrombophilia,
pubmed-meshheading:15247986-Thrombosis
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Thrombosis and a hypercoagulable state in HIV-infected patients.
|
| pubmed:affiliation |
University of Texas Southwestern Medical Center at Dallas, 75390, USA.
|
| pubmed:publicationType |
Journal Article,
Review
|